![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Mgc Pharmaceuticals Limited | LSE:MXC | London | Ordinary Share | AU000000MXC6 | ORD NPV (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 22.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Drug & Proprietary Stores | 4.16M | -20.82M | -0.4749 | -0.59 | 9.65M |
TIDMMXC
RNS Number : 9425K
MGC Pharmaceuticals Limited
31 August 2023
MGC Pharmaceuticals Ltd.
30 June 2023 Preliminary Financial Report
31 August 2023
ASX, LSE: MXC
MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') advises that is has released its 30 June 2023, Preliminary Financial Report, an unaudited Full Year Financial Report required under the Australian Securities Exchange's Listing Rules.
A copy of which can be found at the following URL:
https://www.investi.com.au/api/announcements/mxc/24fd68ea-e40.pdf
-Ends-
Authorised for release by the board of directors, for further information please contact:
MGC Pharmaceuticals Ltd MGC Pharmaceuticals Ltd Roby Zomer Rowan Harland CEO & Managing Director Company Secretary +61 8 6555 2950 +61 8 6555 2950 info@mgcpharma.co.uk info@mgcpharma.co.uk UK IR/PR Advisers UK Brokers IFC Advisory Oberon Capital Graham Herring / Tim Metcalfe / Aimee McCusker / Adam Pollock Zach Cohen +44 203 179 5300 +44 203 934 6630 aimeemccusker@oberoninvestments.com mgcpharma@investor-focus.co.uk adampollock@oberoninvestments.com
About MGC Pharma
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based pharmaceutical company, focused on developing and supplying accessible and ethically produced plant derived medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.
The Company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant derived medicines for the growing demand in the medical markets in Europe, North America and Australasia.
MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.
MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant derived medicines, to be produced in the Company's EU-GMP Certified manufacturing facilities.
MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.
Follow us through our social media channels:
Twitter: @MGC_Pharma
Facebook: @mgcpharmaceuticals
LinkedIn: MGC Pharmaceuticals Ltd.
Instagram: @mgc_pharma
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DOCNKDBQOBKKBFN
(END) Dow Jones Newswires
August 31, 2023 03:44 ET (07:44 GMT)
1 Year Mgc Pharmaceuticals Chart |
1 Month Mgc Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions